1. At a Glance – Small Cap, Big Swings, Even Bigger Drama
Market Cap: ₹159 Cr
Current Price: ₹33.7
3-Month Return: +14.6%
Stock P/E: 17.6
Price to Book: 13.8
ROCE: 41.8%
ROE (Last Year): 187%
Debt to Equity: 3.11
Ladies and gentlemen, welcome to Kimia Biosciences – a ₹159 crore pharma small-cap that behaves like it has consumed too much caffeine and a little bit of insider-level adrenaline. In Q3 FY26 (December 2025 quarter), revenue came in at ₹30.10 crore, PAT at ₹5.44 crore, and EPS at ₹1.15. Operating margins? A spicy 21.79%.
For context, this company was bleeding losses not very long ago. Now suddenly, it is flexing 40%+ ROCE and triple-digit ROE (last year). Either we are witnessing a turnaround story… or this is one of those “pharma quarter specials” where margins pop like Diwali crackers and disappear just as fast.
The stock is up 14.6% in 3 months but still down 29.1% over 1 year. So the market clearly doesn’t know whether to clap or file an FIR.
Let’s investigate.
2. Introduction – From Loss Factory to Margin Machine?
Kimia Biosciences Ltd, incorporated in 1993, is in the business of manufacturing and selling pharmaceutical products. It operates in APIs (Active Pharmaceutical Ingredients), KSMs, intermediates, and is ambitiously stepping into CRAM, CDMO, and CRO services.
Translation for the lazy but intelligent investor:
They make bulk drugs and raw materials that bigger pharma companies use to manufacture finished medicines.
Historically, this company has had more mood swings than a crypto token. Look at the numbers:
- FY23: Net loss ₹9 crore
- FY24: Net loss ₹5 crore
- FY25: Net profit ₹10 crore
- TTM: ₹9 crore
So from red ink to black ink in one financial year. That’s not evolution. That’s a plot twist.
Now Q3 FY26 shows:
- Revenue: ₹30.10 crore
- PAT: ₹5.44 crore
- OPM: 21.79%
This is higher than many mid-sized pharma companies.
Question is:
Is this operational improvement sustainable, or did one or two high-margin export batches do the heavy lifting?
Before we fall in love with margins, let’s understand what they actually do.
3. Business Model – WTF Do They Even Do?
Kimia operates in three verticals:
- Active Pharmaceutical Ingredients (APIs)
- Commercial KSMs, Intermediates & Reagents
- Upcoming CRAM, CDMO, CRO services
APIs are the active components in medicines. If paracetamol is the movie, API is the main actor.
KSMs and intermediates are the raw materials for APIs. So they are climbing up the value chain.
They also have:
- Manufacturing plant in Sohna, Gurgaon
- R&D in Haryana and Hyderabad
- 60+ scientists
- 25+ commercialized products
- 9–10 molecules under development
Molecules under development include heavy hitters like Apixaban, Ticagrelor, Empagliflozin, Linagliptin, Sacubitril Valsartan. These are not your neighbourhood cough syrup ingredients.
Exports form 26% of FY24 revenue. Domestic is 74%.
In September 2024, they received purchase orders worth USD 2.16 lakh from Netherlands entities.
Small order? Yes.
But for
